Calcifying Cystic Odontogenic Tumour: Immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN)

Journal of Oral Pathology and Medicine

Volumn 43, Issue 7, 2014, Pages 545-553

  Prosdócimi, Fábio C ^a   Rodini, Camila O ^a   Sogayar, Mari C ^a   Sousa, Suzana C O M ^a   Xavier, Flávia C A ^b   Paiva, Katiúcia B S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Calcifying cystic odontogenic tumour; EMMPRIN; Matrix metalloproteinases; RECK; Tissue inhibitors of MMPs

Indexed keywords

CD147 ANTIGEN; CYSTEINE; GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; BSG PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MMP14 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; RECK PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE-4; TUMOR PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CALCIFYING CYSTIC ODONTOGENIC TUMOR; CLINICAL ARTICLE; EXTRACELLULAR MATRIX; FEMALE; GHOST CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MANDIBLE TUMOR; MAXILLA TUMOR; ODONTOGENIC TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; STROMA CELL; TUMOR MICROENVIRONMENT; CHEMISTRY; COMPARATIVE STUDY; ENDOTHELIUM CELL; ENZYMOLOGY; EPITHELIUM; MESODERM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD147; ENDOTHELIAL CELLS; EPITHELIUM; EXTRACELLULAR MATRIX; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MESODERM; MIDDLE AGED; NEOPLASM PROTEINS; ODONTOGENIC TUMORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84904404021     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12154     Document Type: Article

References (54)

1. Gorlin RJ, Pindborg JJ, Clausen FP, Vickers RA. The calcifying odontogenic cyst-a possible analogue of the cutaneous calcifying epithelioma of Malherbe. An analysis of fifteen cases. Oral Surg Oral Med Oral Pathol 1962; 15: 1235-43.
2. Ledesma-Montes C, Gorlin RJ, Shear M, et al. International collaborative study on ghost cell odontogenic tumors: calcifying cystic odontogenic tumor, dentinogenic ghost cell tumor and ghost cell odontogenic carcinoma. J Oral Pathol Med 2008; 37: 302-8.
3. Barnes L, Eveson ZW, Reichart PA, Sidransky D. Pathology and genetics of head and neck tumors, World Health Organization Classification of Tumors: International Agency for Research on Cancer (IARC), 2005.
4. Morgan PR. Odontogenic tumors: a review. Periodontol 2000 2011; 57: 160-76.
5. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
6. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochem Biophys Acta 2012; 1825: 29-36.
7. Butler GS, Overall CM. Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 2009; 48: 10830-45.
8. Lopez-Otin C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 2009; 8: 3657-62.
9. Mannello F, Medda V. Nuclear localization of matrix metalloproteinases. Prog Histochem Cytochem 2012; 47: 27-58.
10. Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010; 1803: 39-54.
11. Harper E, Bloch KJ, Gross J. The zymogen of tadpole collagenase. Biochemistry 1971; 10: 3035-41.
12. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002; 52: 255-64.
13. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta 2010; 1803: 3-19.
14. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997; 15: 519-26.
15. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-78.
16. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998; 95: 13221-6.
17. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115(Pt 19): 3719-27.
18. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
19. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
20. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696-701.
21. Pinheiro JJ, Nascimento CF, Freitas VM, de Siqueira AS, Junior SM, Jaeger RG. Invadopodia proteins, cortactin and membrane type I matrix metalloproteinase (MT1-MMP) are expressed in ameloblastoma. Histopathology 2011; 59: 1266-9.
22. Ribeiro AL, Nobre RM, Alves-Junior SM, et al. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and growth factors regulate the aggressiveness and proliferative activity of keratocystic odontogenic tumors. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 487-96.
23. Ribeiro BF, Ferreira de Araujo CR, dos Santos BR, de Almeida FR. Immunohistochemical expression of matrix metalloproteinases 1, 2, 7, 9, and 26 in the calcifying cystic odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 609-15.
24. Siqueira AS, Carvalho MR, Monteiro AC, Freitas VM, Jaeger RG, Pinheiro JJ. Matrix metalloproteinases, TIMPs and growth factors regulating ameloblastoma behaviour. Histopathology 2010; 57: 128-37.
25. Tsuneki M, Maruyama S, Yamazaki M, Cheng J, Saku T. Podoplanin expression profiles characteristic of odontogenic tumor-specific tissue architectures. Pathol Res Pract 2012; 208: 140-6.
26. Gong Y, Wang L, Wang H, Li T, Chen X. The expression of NF-kappaB, Ki-67 and MMP-9 in CCOT, DGCT and GCOC. Oral Oncol 2009; 45: 515-20.
27. Moore CS, Crocker SJ. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012; 180: 12-6.
28. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol 2011; 12: 233.
29. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001; 108: 817-29.
30. Fata JE, Leco KJ, Voura EB, et al. Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest 2001; 108: 831-41.
31. Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006; 176: 721-5.
32. Qi JH, Ebrahem Q, Ali M, et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice. PLoS ONE 2013; 8: e55667.
33. Kang KH, Park SY, Rho SB, Lee JH. Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. Cardiovasc Res 2008; 79: 150-60.
34. Ebrahem Q, Qi JH, Sugimoto M, et al. Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3. Invest Ophthalmol Vis Sci 2011; 52: 6117-23.
35. Karathanasi V, Tosios KI, Nikitakis NG, et al. TGF-beta1, Smad-2/-3, Smad-1/-5/-8, and Smad-4 signaling factors are expressed in ameloblastomas, adenomatoid odontogenic tumors, and calcifying cystic odontogenic tumors: an immunohistochemical study. J Oral Pathol Med 2013; 42: 415-23.
36. Melendez-Zajgla J, Del PL, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 2008; 7: 85.
37. Bigg HF, Morrison CJ, Butler GS, et al. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 2001; 61: 3610-8.
38. Liu YE, Wang M, Greene J, et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997; 272: 20479-83.
39. Troeberg L, Tanaka M, Wait R, Shi YE, Brew K, Nagase H. E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A). Biochemistry 2002; 41: 15025-35.
40. Zhang J, Cao YJ, Zhao YG, Sang QX, Duan EK. Expression of matrix metalloproteinase-26 and tissue inhibitor of metalloproteinase-4 in human normal cytotrophoblast cells and a choriocarcinoma cell line, JEG-3. Mol Hum Reprod 2002; 8: 659-66.
41. Noda M, Takahashi C. Recklessness as a hallmark of aggressive cancer. Cancer Sci 2007; 98: 1659-65.
42. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
43. Sasahara RM, Brochado SM, Takahashi C, et al. Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detect Prev 2002; 26: 435-43.
44. Takagi S, Simizu S, Osada H. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 2009; 69: 1502-8.
45. Omura A, Matsuzaki T, Mio K, et al. RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. J Biol Chem 2009; 284: 3461-9.
46. Echizenya M, Kondo S, Takahashi R, et al. The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors. Oncogene 2005; 24: 5850-7.
47. Welm B, Mott J, Werb Z. Developmental biology: vasculogenesis is a wreck without RECK. Curr Biol 2002; 12: R209-11.
48. Kumamoto H, Ooya K. Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. J Oral Pathol Med 2006; 35: 345-51.
49. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-9.
50. Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997; 272: 24-7.
51. Kanekura T, Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 2010; 57: 149-54.
52. Richard V, Pillai MR. The stem cell code in oral epithelial tumorigenesis: 'the cancer stem cell shift hypothesis'. Biochim Biophys Acta 2010; 1806: 146-62.
53. Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. Cancer Genomics Proteomics 2010; 7: 157-69.
54. Ali MA. Expression of extracellular matrix metalloproteinase inducer in odontogenic cysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 258-63.